Novogen (KZIA) Competitors

$13.66 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$12.77 -0.89 (-6.52%)

As of 05/22/2026 06:34 PM Eastern

KZIA vs. ATRA, EXOZ, EDSA, BHST, and CTOR

Should you buy Novogen stock or one of its competitors? MarketBeat compares Novogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novogen include Atara Biotherapeutics (ATRA), eXoZymes (EXOZ), Edesa Biotech (EDSA), BioHarvest Sciences (BHST), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 3.06%. Novogen has a consensus price target of $21.00, indicating a potential upside of 53.73%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Atara Biotherapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market. Comparatively, Novogen has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market.

Novogen has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Novogen's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Novogen	N/A	N/A	N/A

In the previous week, Atara Biotherapeutics had 21 more articles in the media than Novogen. MarketBeat recorded 21 mentions for Atara Biotherapeutics and 0 mentions for Novogen. Atara Biotherapeutics' average media sentiment score of 0.15 beat Novogen's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Novogen	Neutral

Atara Biotherapeutics has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.73	$32.69M	-$0.67	N/A
Novogen	$30K	751.30	-$13.41M	N/A	N/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novogen beats Atara Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Novogen compare to eXoZymes?

Novogen (NASDAQ:KZIA) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Novogen's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
eXoZymes	N/A	-220.63%	-141.26%

In the previous week, Novogen's average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
eXoZymes	Neutral

eXoZymes has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	751.30	-$13.41M	N/A	N/A
eXoZymes	$70K	1,201.74	-$9.16M	-$1.14	N/A

30.9% of Novogen shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novogen currently has a consensus target price of $21.00, indicating a potential upside of 53.73%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Novogen has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, suggesting that its share price is 185% more volatile than the broader market.

Summary

Novogen beats eXoZymes on 6 of the 11 factors compared between the two stocks.

How does Novogen compare to Edesa Biotech?

Novogen (NASDAQ:KZIA) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Edesa Biotech had 6 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Edesa Biotech and 0 mentions for Novogen. Edesa Biotech's average media sentiment score of 0.08 beat Novogen's score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Neutral
Edesa Biotech	Neutral

Novogen's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Edesa Biotech	N/A	-286.52%	-75.36%

Edesa Biotech has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	751.30	-$13.41M	N/A	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Novogen has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Novogen presently has a consensus price target of $21.00, indicating a potential upside of 53.73%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 52.20%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novogen is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.9% of Novogen shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Novogen beats Edesa Biotech on 8 of the 12 factors compared between the two stocks.

How does Novogen compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

30.9% of Novogen shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioHarvest Sciences had 7 more articles in the media than Novogen. MarketBeat recorded 7 mentions for BioHarvest Sciences and 0 mentions for Novogen. Novogen's average media sentiment score of 0.00 beat BioHarvest Sciences' score of -0.30 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Novogen	Neutral

BioHarvest Sciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Novogen has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market.

BioHarvest Sciences currently has a consensus price target of $10.00, suggesting a potential upside of 159.07%. Novogen has a consensus price target of $21.00, suggesting a potential upside of 53.73%. Given BioHarvest Sciences' higher possible upside, equities research analysts clearly believe BioHarvest Sciences is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Novogen has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Novogen's return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Novogen	N/A	N/A	N/A

BioHarvest Sciences has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A
Novogen	$30K	751.30	-$13.41M	N/A	N/A

Summary

Novogen beats BioHarvest Sciences on 10 of the 14 factors compared between the two stocks.

How does Novogen compare to Citius Oncology?

Novogen (NASDAQ:KZIA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Novogen's return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Citius Oncology	N/A	-99.47%	-42.16%

Novogen has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.56, indicating that its share price is 256% more volatile than the broader market.

Novogen presently has a consensus price target of $21.00, indicating a potential upside of 53.73%. Citius Oncology has a consensus price target of $6.00, indicating a potential upside of 614.37%. Given Citius Oncology's higher probable upside, analysts plainly believe Citius Oncology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Novogen has higher revenue and earnings than Citius Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	751.30	-$13.41M	N/A	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

In the previous week, Novogen's average media sentiment score of 0.00 equaled Citius Oncology'saverage media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
Citius Oncology	Neutral

30.9% of Novogen shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 7.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Novogen beats Citius Oncology on 6 of the 10 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.59M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	21.00	25.66
Price / Sales	751.30	323.98	558.19	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-2.56	7.09	10.40	7.14
Net Income	-$13.41M	$24.45M	$3.57B	$335.98M
7 Day Performance	13.08%	6.38%	6.40%	4.11%
1 Month Performance	11.42%	2.43%	3.55%	2.52%
1 Year Performance	281.56%	62.98%	34.13%	35.04%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	1.5023 of 5 stars	$13.66 flat	$21.00 +53.7%	+281.6%	$22.59M	$30K	N/A	12	Gap Down
ATRA Atara Biotherapeutics	1.1719 of 5 stars	$9.41 +2.8%	$9.50 +1.0%	+37.3%	$82.44M	$120.77M	N/A	330	Gap Down
EXOZ eXoZymes	0.1264 of 5 stars	$9.50 -0.5%	N/A	-33.4%	$80.97M	$70K	N/A	29	Gap Up
EDSA Edesa Biotech	1.6892 of 5 stars	$11.95 +32.8%	$5.00 -58.2%	+433.7%	$80.03M	N/A	N/A	20	Gap Up
BHST BioHarvest Sciences	2.4533 of 5 stars	$3.92 -1.0%	$10.00 +155.1%	-38.6%	$77.68M	$34.51M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. ATRA, EXOZ, EDSA, BHST, and CTOR

How does Novogen compare to Atara Biotherapeutics?

Summary

How does Novogen compare to eXoZymes?

Summary

How does Novogen compare to Edesa Biotech?

Summary

How does Novogen compare to BioHarvest Sciences?

Summary

How does Novogen compare to Citius Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. ATRA, EXOZ, EDSA, BHST, and CTOR

How does Novogen compare to Atara Biotherapeutics?

Do analysts rate ATRA or KZIA?

Which has more risk & volatility, ATRA or KZIA?

Is ATRA or KZIA more profitable?

Does the media favor ATRA or KZIA?

Which has higher earnings and valuation, ATRA or KZIA?

Do institutionals & insiders hold more shares of ATRA or KZIA?

Summary

How does Novogen compare to eXoZymes?

Is KZIA or EXOZ more profitable?

Does the media favor KZIA or EXOZ?

Which has better valuation & earnings, KZIA or EXOZ?

Do insiders & institutionals believe in KZIA or EXOZ?

Do analysts recommend KZIA or EXOZ?

Which has more risk & volatility, KZIA or EXOZ?

Summary

How does Novogen compare to Edesa Biotech?

Does the media refer more to KZIA or EDSA?

Is KZIA or EDSA more profitable?

Which has preferable earnings & valuation, KZIA or EDSA?

Which has more volatility and risk, KZIA or EDSA?

Do analysts prefer KZIA or EDSA?

Do institutionals and insiders believe in KZIA or EDSA?

Summary

How does Novogen compare to BioHarvest Sciences?

Do insiders and institutionals hold more shares of BHST or KZIA?

Does the media favor BHST or KZIA?

Which has more risk and volatility, BHST or KZIA?

Do analysts rate BHST or KZIA?

Is BHST or KZIA more profitable?

Which has better valuation & earnings, BHST or KZIA?

Summary

How does Novogen compare to Citius Oncology?

Is KZIA or CTOR more profitable?

Which has more volatility & risk, KZIA or CTOR?

Do analysts prefer KZIA or CTOR?

Which has stronger earnings & valuation, KZIA or CTOR?

Does the media favor KZIA or CTOR?

Do institutionals & insiders believe in KZIA or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools